Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Infectious Diseases Information Center

Study to Assess Antiviral Antibody Cocktail for COVID-19 Prevention Begins

Diana Ernst, RPh

July 9, 2020

A phase 3 trial evaluating an investigational antiviral antibody cocktail, REGN-COV2, for the prevention of COVID-19 has been initiated by Regeneron Pharmaceuticals.

Neurology Information Center

Galcanezumab Linked to Improved Work Productivity in Patients With Migraine

Diana Ernst, RPh

June 22, 2020

Galcanezumab was found to significantly improve work productivity and reduce interictal burden in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.

Sleep Information Center

Dayvigo Now Available for Insomnia Treatment

Diana Ernst, RPh

June 16, 2020

Dayvigo (lemborexant; Eisai) is now available for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adult patients.

Infectious Diseases Information Center

Early Data Show Potential Benefit of Acalabrutinib in Severe COVID-19

Diana Ernst, RPh

June 10, 2020

Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.

Ob/Gyn Information Center

Oriahnn Approved for Heavy Menstrual Bleeding Due to Uterine Fibroids

Diana Ernst, RPh

June 3, 2020

The FDA has approved Oriahnn™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules; AbbVie) for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.

Hematology Information Center

FDA Approval Expands Access of Artesunate for Malaria Treatment

Diana Ernst, RPh

May 29, 2020

The FDA has approved Artesunate for Injection (Amivas) for the initial treatment of severe malaria in adult and pediatric patients.

Infectious Diseases Information Center

NIH Trial Evaluating Remdesivir Plus Baricitinib for COVID-19 Initiated

Diana Ernst, RPh

May 13, 2020

Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.

Vaccine Information Center

AAP: Declines in Immunization During COVID-19 Pandemic Concerning

Diana Ernst, RPh

May 12, 2020

The AAP has issued a statement regarding recent data published by the Centers for Disease Control and Prevention (CDC) about a decline in pediatric vaccination during the COVID-19 pandemic.

Infectious Diseases Information Center

FDA Urges Recovered COVID-19 Patients to Donate Plasma

Diana Ernst, RPh

May 1, 2020

The FDA has launched a new webpage with information for recovered individuals who were infected with coronavirus disease 2019 (COVID-19) on where they can go to donate plasma to aid in the treatment of severely ill patients.

Psychiatry Information Center

FDA: Guidance on Digital Therapeutics for Psychiatric Disorders During COVID-19

Diana Ernst, RPh

April 29, 2020

The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.

Next post in Psychiatry Information Center